MarketCap
Facebook
X
Telegram
CytomX Therapeutics Income Statement 2025-2011 | CTMX
Brief overview of profit and loss at CytomX Therapeutics
This overview is based on financial performance over the past five years. Revenue reported by CytomX Therapeutics was $68.4 million at the beginning of the period and $76.2 million at the end. Overall revenue changed by +11.4%, equal to an annualized rate of about 2.2%. The revenue trend is close to stagnation.
EBITDA was −21.7 million dollars at the beginning and −21.2 million dollars at the end of the period (+2.4%). The operating result changed at a rate similar to sales. The EBITDA share of revenue changed from −31.7% to −27.8%. Higher profitability strengthens the quality of operating growth.
Comparing the endpoints shows a move from −24 million dollars to −17.4 million dollars. Losses became smaller, but the business remains unprofitable.
Financial takeaway
The five-year picture requires weighing both strengths and weaknesses. The strongest signals are an improving EBITDA margin and net-income growth. The main areas of concern are a low EBITDA margin and limited revenue growth. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement CytomX Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
931 M | 52.4 M | 185 M | 119 M | 283 M | 305 M | 377 M | 697 M | 1.02 B | 411 M | 135 M | - | - | - | - |
Shares |
138 M | 84.4 M | 73.8 M | 65.7 M | 65.3 M | 46.6 M | 45.3 M | 41.7 M | 37.2 M | 36.2 M | 8.6 M | - | - | - | - |
Historical Prices |
6.75 | 0.62 | 2.51 | 1.81 | 4.33 | 6.55 | 8.31 | 15.1 | 21.1 | 11 | 20.9 | - | - | - | - |
Net Income |
-17.4 M | 31.9 M | -569 K | -99.3 M | -34.8 M | -24 M | -133 M | -84.6 M | -43.1 M | -58.9 M | -35.4 M | -30.3 M | -15.1 M | - | - |
Revenue |
76.2 M | 138 M | 101 M | 53.2 M | 37.3 M | 68.4 M | 26.9 M | 59.5 M | 71.6 M | 15 M | 7.71 M | 5.08 M | 888 K | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 7.71 M | 5.08 M | 888 K | - | - |
Operating Income |
-22.4 M | 25 M | -6.48 M | -101 M | -34.9 M | -24.1 M | -141 M | -77.9 M | -46.3 M | -59.6 M | -33.2 M | -29.8 M | -15 M | - | - |
Interest Expense |
28 K | -38 K | -30 K | 340 K | 7 K | -29 K | -135 K | -68 K | -27 K | 1.69 M | 1.73 M | 487 K | 254 K | - | - |
EBITDA |
-21.2 M | 26.6 M | -4.48 M | -99 M | -32.3 M | -21.7 M | -139 M | -76 M | -44.6 M | -57.9 M | -32 M | -29 M | -14.3 M | - | - |
Operating Expenses |
98.6 M | 113 M | 108 M | 154 M | 46 M | 31.2 M | 168 M | 137 M | 118 M | 74.6 M | 40.9 M | 34.8 M | 15.8 M | - | - |
General and Administrative Expenses |
29.8 M | 29.7 M | 30 M | 42.8 M | 9.46 M | 9.14 M | 36.8 M | 33.5 M | 25.6 M | 19.9 M | 12.6 M | 6.54 M | 4.95 M | - | - |
All numbers in USD currency
Quarterly Income Statement CytomX Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
219 M | 177 M | 165 M | 129 M | 87.1 M | 85.1 M | 84.9 M | 82 M | 80.7 M | 66.5 M | 66.2 M | - | 65.9 M | 65.5 M | 65.4 M | 65.4 M | 65.2 M | 65.1 M | 61 M | 48.3 M | 46.2 M | 46.1 M | 45.7 M | 45.5 M | 45.4 M | 45.3 M | 45.1 M | 45.1 M | 43.9 M | 39 M | 38.6 M | 38.5 M | 36.9 M | 36.8 M | 36.5 M | 36.5 M | 36.3 M | 36.1 M | 36.1 M | 36 M | 1.04 M | 1 M | 997 K | 997 K | 979 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-20.7 M | -18.2 M | -14.2 M | -154 K | 23.5 M | 5.74 M | -6.53 M | 13.8 M | 2.99 M | -1.09 M | -3.31 M | - | -29.1 M | -29.5 M | -32 M | - | -22.6 M | -19.2 M | -15.6 M | - | -14.7 M | -15.7 M | 12.2 M | -35.5 M | -23.7 M | -29 M | -14.1 M | -32.2 M | -23.4 M | -13.4 M | -15.5 M | 621 K | -10.2 M | -25.2 M | -8.26 M | -14 M | -14.7 M | -14.2 M | -16 M | -11.5 M | -11.9 M | -5.81 M | -6.21 M | -4.79 M | -3.59 M | -4.93 M | -17 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
1.42 M | 10.3 M | 5.96 M | 18.7 M | 50.9 M | 33.4 M | 25.1 M | 41.5 M | 26.4 M | 24.7 M | 23.5 M | - | 11.1 M | 12.9 M | 9.04 M | - | 17.6 M | 16.3 M | 16 M | - | 17.8 M | 16.6 M | 49.6 M | 8.28 M | 10.7 M | 9.01 M | 29.5 M | 11.5 M | 12.5 M | 21.3 M | 14.2 M | 27.1 M | 24.1 M | 8.75 M | 11.7 M | 6.27 M | 3.45 M | 3.09 M | 2.22 M | 1.99 M | 1.94 M | 2.04 M | 1.74 M | 1.86 M | 1.92 M | 666 K | 635 K | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-23.8 M | -19.7 M | -15.8 M | -1.29 M | 22.6 M | 4.11 M | -8.45 M | 11.7 M | 3.12 M | -3.35 M | -5.65 M | - | -29.7 M | -30.1 M | -32.1 M | - | -22.6 M | -19.2 M | -15.6 M | - | -14.9 M | -16.1 M | -2.79 M | - | -25.7 M | -31.2 M | -16.6 M | -25.8 M | -23.2 M | -13.3 M | -15.6 M | - | -11 M | -25.4 M | -8.61 M | - | -14.9 M | -14.3 M | -16.2 M | - | -11.3 M | -5.54 M | -4.87 M | - | -3.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
18 K | -7 K | 5 K | 17 K | 11 K | -7 K | -2 K | -11 K | -7 K | -47 K | 15 K | - | 30 K | 296 K | 13 K | - | -13 K | -82 K | 5 K | - | -15 K | 5 K | 12 K | - | 22 K | -88 K | -61 K | - | 29 K | 61 K | -140 K | - | -47 K | -174 K | 206 K | - | 482 K | 465 K | 353 K | - | 718 K | 408 K | 230 K | - | 117 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-23.7 M | -19.6 M | - | - | 22.7 M | - | - | 11.7 M | - | - | -5.62 M | - | -29.6 M | -30.1 M | -32 M | - | -22.5 M | -19.2 M | -15.6 M | - | -14.8 M | -16.1 M | -2.76 M | - | -25.6 M | -31.2 M | -15.9 M | -25.8 M | -23.1 M | -12.5 M | -15.3 M | - | -9.78 M | -25 M | -8.22 M | - | -14.5 M | -13.8 M | -15.8 M | - | -11 M | -5.24 M | -4.6 M | - | -2.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
25.2 M | 29.9 M | 21.7 M | 19.9 M | 28.3 M | 29.3 M | 33.6 M | 29.8 M | 23.3 M | 28.1 M | 29.2 M | - | 40.9 M | 42.9 M | 41.1 M | - | 40.2 M | 35.5 M | 31.6 M | - | 32.7 M | 32.7 M | 52.4 M | - | 36.4 M | 40.2 M | 46 M | - | 35.7 M | 34.6 M | 29.8 M | - | 35.2 M | 34.1 M | 20.3 M | - | 18.4 M | 17.4 M | 18.4 M | - | 13.2 M | 7.58 M | 6.61 M | - | 5.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.6 M | 10.7 M | 6.43 M | 6.62 M | 9.43 M | 7.95 M | 8.4 M | 7.75 M | 6.81 M | 7.4 M | 7.98 M | - | 10.5 M | 11.7 M | 10.5 M | - | 11.1 M | 9.39 M | 9.23 M | - | 8.63 M | 8.68 M | 9.57 M | - | 8.46 M | 9.41 M | 9.67 M | - | 8.14 M | 9.04 M | 7.36 M | - | 6.25 M | 6.05 M | 5.69 M | - | 5.03 M | 4.65 M | 5.04 M | - | 4.05 M | 2.55 M | 1.95 M | - | 1.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company CytomX Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
